Tempus AI, Inc. (TEM)
NASDAQ: TEM · Real-Time Price · USD
94.47
-1.92 (-1.99%)
At close: Oct 13, 2025, 4:00 PM EDT
94.89
+0.42 (0.44%)
After-hours: Oct 13, 2025, 7:59 PM EDT
Tempus AI Revenue
Tempus AI had revenue of $314.64M in the quarter ending June 30, 2025, with 89.57% growth. This brings the company's revenue in the last twelve months to $951.98M, up 59.84% year-over-year. In the year 2024, Tempus AI had annual revenue of $693.40M with 30.38% growth.
Revenue (ttm)
$951.98M
Revenue Growth
+59.84%
P/S Ratio
16.81
Revenue / Employee
$396,659
Employees
2,400
Market Cap
16.41B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 693.40M | 161.58M | 30.38% |
| Dec 31, 2023 | 531.82M | 211.15M | 65.85% |
| Dec 31, 2022 | 320.67M | 62.82M | 24.36% |
| Dec 31, 2021 | 257.85M | 69.85M | 37.15% |
| Dec 31, 2020 | 188.00M | 125.95M | 202.95% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
TEM News
- 4 days ago - Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy - Business Wire
- 4 days ago - Tempus AI's $100 Breakout — Billionaire Cliff Asness Reaps 60% Windfall - Benzinga
- 12 days ago - Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast Density - Business Wire
- 21 days ago - Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device - Business Wire
- 4 weeks ago - Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease - PRNewsWire
- 4 weeks ago - Tempus AI stock is cheap as Murrey Math Lines points to more gains - Invezz
- 4 weeks ago - Tempus AI: Is TEM Stock A 10x Growth Story? - Forbes
- 4 weeks ago - Tempus AI Gains FDA Clearance For Updated Pixel To Boost Accuracy And Efficiency In Cardiac Imaging - Benzinga